← back to search

Johanna Tischer

Ludwig-Maximilians-Universität München · DE
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Medicine, Internal medicine, Transplantation, Myeloid leukemia, Hematopoietic stem cell transplantation, and Cumulative incidence.
h-index
citations
1,493
works
40
NIH funding
primary concept
email

Recent publications

Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party
Bone Marrow Transplantation 2025cited by 3position: middledoi
Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT
Bone Marrow Transplantation 2025cited by 0position: middledoi
Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
Clinical Cancer Research 2024cited by 23position: middledoi
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies
Cancers 2024cited by 12position: middledoi
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
Journal of Translational Medicine 2023cited by 18position: middledoi
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study
Frontiers in Immunology 2023cited by 7position: middledoi
Smart Conditioning with Venetoclax Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies
Preprints.org 2023cited by 3position: middledoi
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome
British Journal of Haematology 2023cited by 1position: middledoi
Data from Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
2023cited by 0position: middledoi
Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
Clinical Cancer Research 2022cited by 41position: middledoi
Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia
Transplantation and Cellular Therapy 2022cited by 12position: middledoi
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT
Blood 2022cited by 1position: middledoi
Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
Bone Marrow Transplantation 2021cited by 100position: middledoi
Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection
HemaSphere 2021cited by 32position: middledoi
Expression of Surface-associated 82 kDa proMMP-9 in Lymphatic Leukemia Blast Cells Differentially Correlates With Prognosis
Anticancer Research 2021cited by 1position: middledoi
Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman–Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT)
Bone Marrow Transplantation 2020cited by 46position: middledoi
FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation 2020cited by 42position: middledoi
Prognostic value of perioperative red blood cell transfusion and anemia on survival and recurrence in oral squamous cell carcinoma
Oral Oncology 2020cited by 14position: middledoi
Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT
British Journal of Haematology 2020cited by 14position: middledoi
Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia – a study of the Acute Leukemia Working Party of the EBMT
Leukemia & lymphoma/Leukemia and lymphoma 2020cited by 13position: middledoi
P07.01 CD19 CAR T-cells for relapsed/refractory diffuse large B-cell Lymphoma: real-world data from LMU Munich
2020cited by 2position: middledoi
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT
Bone Marrow Transplantation 2019cited by 43position: middledoi
Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation 2019cited by 39position: middledoi
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Journal of Hematology & Oncology 2019cited by 38position: middledoi
Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party
Biology of Blood and Marrow Transplantation 2019cited by 33position: middledoi
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT
British Journal of Haematology 2018cited by 113position: middledoi
Haploidentical <i>versus</i> unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT
Haematologica 2018cited by 92position: middledoi
European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation
Leukemia 2018cited by 60position: middledoi
A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia
Haematologica 2017cited by 140position: middledoi
Characteristics and Outcome of Patients After Allogeneic Hematopoietic Stem Cell Transplantation Treated With Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome*
Critical Care Medicine 2017cited by 80position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Arnon Nagler · University of Naples Federico II17 papers (2015–2025)Myriam Labopin · Inserm16 papers (2014–2025)Nicolaus Kröger · Universität Ulm16 papers (2013–2025)Jürgen Finke · University of Education Freiburg16 papers (2014–2025)Mohamad Mohty · Inserm15 papers (2014–2025)Arnold Ganser · Radboud University Medical Center12 papers (2012–2025)Dietrich W. Beelen · West German Heart and Vascular Center Essen10 papers (2013–2022)Matthias Stelljes · The Ohio State University9 papers (2016–2025)Fabio Ciceri · Vita-Salute San Raffaele University9 papers (2015–2025)Christoph Schmid · Cancer Research Center7 papers (2012–2023)Gesine Bug · German Cancer Research Center7 papers (2012–2024)Johannes Schetelig · Center for Systems Biology Dresden7 papers (2014–2025) · 6 papers (2018–2022)Bipin N. Savani · Medical College of Wisconsin6 papers (2016–2021)Donald Bunjes · Ludwig-Maximilians-Universität München6 papers (2012–2022)Didier Blaise · Institut Pprime6 papers (2014–2024) · 5 papers (2016–2025)Hermann Einsele · Ovarian Cancer Research Alliance5 papers (2016–2025)Wolfgang Bethge · University Children's Hospital Tübingen5 papers (2016–2025)Mauricette Michallet · Centre de Recherche en Cancérologie de Lyon4 papers (2016–2019)